Literature DB >> 6538772

In vitro antimicrobial activity of aztreonam alone and in combination against bacterial isolates from pediatric patients.

H R Stutman, D F Welch, R K Scribner, M I Marks.   

Abstract

We examined 134 pediatric clinical isolates of Enterobacteriaceae, Pseudomonas aeruginosa, and gram-positive cocci for susceptibility to aztreonam alone and in combination with seven other antibiotics. All 98 gram-negative isolates were susceptible to aztreonam with similar inhibitory and bactericidal activity. Combinations of aztreonam with cefoxitin, ampicillin, or clindamycin were generally indifferent or additive. Synergism was occasionally seen against enteric organisms with aztreonam plus cefoxitin or clindamycin. Combinations of tobramycin and aztreonam were synergistic (62%) against P. aeruginosa; aztreonam plus piperacillin or ticarcillin was additive. Aztreonam did not affect the activity of nafcillin against Staphylococcus aureus, or of ampicillin against species of Streptococcus group B or D. Antagonism was seen only with aztreonam plus cefoxitin against Enterobacter species, but not at clinically significant concentrations. Several combinations of antibiotics with aztreonam should be appropriate for initial therapy of infections in children without major risks of antibacterial antagonism.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6538772      PMCID: PMC185476          DOI: 10.1128/AAC.25.2.212

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  16 in total

1.  Pharmacokinetics of the monobactam SQ 26,776 after single intravenous doses in healthy subjects.

Authors:  E A Swabb; M A Leitz; F G Pilkiewicz; A A Sugerman
Journal:  J Antimicrob Chemother       Date:  1981-12       Impact factor: 5.790

2.  Spectrophotometric assessment of dose-response curves for single antimicrobial agents and antimicrobial combinations.

Authors:  T C King; D J Krogstad
Journal:  J Infect Dis       Date:  1983-04       Impact factor: 5.226

3.  Novel resistance selected by the new expanded-spectrum cephalosporins: a concern.

Authors:  C C Sanders
Journal:  J Infect Dis       Date:  1983-03       Impact factor: 5.226

4.  Antibacterial activity of the monobactam SQ 26,776 against antibiotic resistant enterobacteria, including Serratia spp.

Authors:  D S Reeves; M J Bywater; H A Holt
Journal:  J Antimicrob Chemother       Date:  1981-12       Impact factor: 5.790

5.  Monocyclic beta-lactam antibiotics produced by bacteria.

Authors:  R B Sykes; C M Cimarusti; D P Bonner; K Bush; D M Floyd; N H Georgopapadakou; W M Koster; W C Liu; W L Parker; P A Principe; M L Rathnum; W A Slusarchyk; W H Trejo; J S Wells
Journal:  Nature       Date:  1981-06-11       Impact factor: 49.962

6.  The assessment of antimicrobial combinations.

Authors:  T C King; D Schlessinger; D J Krogstad
Journal:  Rev Infect Dis       Date:  1981 May-Jun

7.  Comparison of methods for assessing in vitro antibiotic synergism against Pseudomonas and Serratia.

Authors:  R J Weinstein; L S Young; W L Hewitt
Journal:  J Lab Clin Med       Date:  1975-11

8.  Influence of clindamycin on derepression of beta-lactamases in Enterobacter spp. and Pseudomonas aeruginosa.

Authors:  C C Sanders; W E Sanders; R V Goering
Journal:  Antimicrob Agents Chemother       Date:  1983-07       Impact factor: 5.191

9.  In vitro activity of cefoxitin, alone and in combination with aminoglycoside or other beta-lactam antibiotics against common gram-negative pathogens.

Authors:  S M Markowitz; D J Sibilla
Journal:  Chemotherapy       Date:  1983       Impact factor: 2.544

10.  In vitro activity of azthreonam, a monobactam antibiotic.

Authors:  N V Jacobus; M C Ferreira; M Barza
Journal:  Antimicrob Agents Chemother       Date:  1982-11       Impact factor: 5.191

View more
  5 in total

Review 1.  [A comparative review of combination therapy: 2 beta-lactams versus beta-lactam plus aminoglycoside].

Authors:  P Dejace; J Klastersky
Journal:  Infection       Date:  1987       Impact factor: 3.553

2.  Evaluation of aztreonam in the treatment of severe bacterial infections.

Authors:  J Romero-Vivas; M Rodríguez-Créixems; E Bouza; T Hellín; A Guerrero; J Martínez-Beltrán; M García de la Torre
Journal:  Antimicrob Agents Chemother       Date:  1985-08       Impact factor: 5.191

Review 3.  Aztreonam. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  R N Brogden; R C Heel
Journal:  Drugs       Date:  1986-02       Impact factor: 9.546

Review 4.  Infectious disease: how to manage Gram-positive and Gram-negative pathogen conundrums with dual beta-lactam therapy.

Authors:  Alireza FakhriRavari; Brenda Simiyu; Taylor Morrisette; Yewande Dayo; Jacinda C Abdul-Mutakabbir
Journal:  Drugs Context       Date:  2022-01-20

5.  Synergistic, collaterally sensitive β-lactam combinations suppress resistance in MRSA.

Authors:  Patrick R Gonzales; Mitchell W Pesesky; Renee Bouley; Anna Ballard; Brent A Biddy; Mark A Suckow; William R Wolter; Valerie A Schroeder; Carey-Ann D Burnham; Shahriar Mobashery; Mayland Chang; Gautam Dantas
Journal:  Nat Chem Biol       Date:  2015-09-14       Impact factor: 15.040

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.